However, KRAS mutations, which are often present in both of these carcinomas, nevertheless have the vast majority mutations on residues 12, 13 and 61 for both cancers suggesting that the mutation type may only have a small impact on the uniformity assumption [25]. The gene discussed is KRAS; the disease is carcinoma.